India Pharma Outlook Team | Wednesday, 18 November 2026
Biocon Executive Chairperson Kiran Mazumdar-Shaw believes artificial intelligence (AI) could transform drug development by cutting the time needed to bring a molecule from the laboratory to patients from five to seven years to just one or two years.
Speaking on the first day of the Bengaluru Tech Summit 2026, she highlighted how AI could reshape drug discovery, clinical trials and diagnostics.
Shaw said the opportunity goes beyond incremental improvements. Instead, AI could fundamentally change how scientists discover, develop and innovate new medicines, opening new possibilities for precision and personalized medicine.
Shaw highlighted AI’s potential to accelerate the entire drug development journey, including clinical trials. She said researchers must identify suitable patients and generate early trial readouts to move promising molecules towards patients faster.
She also questioned the traditional approach of studying one biological target at a time. AI could help scientists connect genomics, chemical pathways and neural networks to understand complex biological systems and develop next-generation treatments.
According to Shaw, this approach could also improve early disease detection, including identifying the first cancer cell before patients reach advanced stages.
The shift has already begun in research laboratories. Autonomous wet labs now use AI for high-throughput screening and real-time analytics. However, scientists must validate their models through clinical trials before they can establish their effectiveness.
Also Read: 5 Women Leaders Driving India's Pharma and Healthcare Innovation
Shaw stressed that regulation must keep pace with scientific discovery. She highlighted ongoing discussions in Karnataka around a regulatory sandbox that could help researchers validate proofs of concept faster.
She also described biology as the most important frontier for AI, where technology can help scientists connect the dots across complex biological processes. For Biocon, the opportunity extends beyond drug discovery. AI could also support diagnostics, biotechnology research and the development of innovative therapies.
As India strengthens its biotechnology capabilities, Shaw urged the country to embrace this opportunity. She emphasized that AI could redefine drug innovation, and India should not lose its chance to lead this transformation.